Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 4-5x per week according to the following cadence:
Mondays: BioBucks: Stock Analysis & Biotech Catalysts
Wednesdays: CRISPR Corner: Monthly gene editing news
Thursdays: Insiders Track: Public & Private Biotech Markets
Fridays: Sweat Equity: Your Weekly Biotech Fix
Sundays: Building Biotech: Strategic Topics
In addition we aim to put out 1-2 podcasts episodes per week. One on Tue/Wed focusing on interesting industry related content and a second on Fri/Sat which will likely be more of a news recap.
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
Welcome to today’s episode, where we dive into the latest developments shaping the biotech industry. We’ll explore recent financial performance reports, mergers and acquisitions, strategic drug licensing deals, and fresh funding rounds that are setting the stage for future innovation. Along the way, we’ll highlight key trends, including the rising interest in drug development for neurological disorders, the pivot towards repurposing cancer drugs for autoimmune diseases, and the growing impact of smaller venture capital firms in supporting early-stage biotech. Tune in for a quick snapshot of the current biotech landscape, packed with insights on cutting-edge drug development, strategic partnerships, and the financial moves driving the industry forward.
📣🎙️ TODAY’S PODCAST:
[ 0:00 ] Intro
[ 1:00 ] Abbvie pays $1.4B to cross blood-brain barrier
[ 2:20 ] GSK pays $300M for another China BiFx
[ 4:25 ] Large vs. Small VCs carving out niches
[ 6:30 ] Jade reverse merges onto NASDAQ
[ 7:50 ] Amgen makes news in obesity space
[ 8:30 ] Nobel Newco via David Baker
[ 10:45 ] New biotech meground - Axonis
[ 12:30 ] Biotech career tips - networking
[ 13:40 ] Trump vs Harris - biotech implications
[ 15:35 ] Where are they now? Biotechs most innovative
[ 18:00 ] Conclusion
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
Your Weekly Biotech News Fix